Table 5. Association between PON1 Q192R polymorphism genotype frequencies and clinic-pathological parameters of the breast cancer patients.
| Age | Menopausal | BMI(kg/m2) | Lymph node status | AJCC stage | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Premenopausal | Postmenopausal | ≤24.9 | 25.0-29.9 | ≥30.0 | N0 | N1 | I | II | III | IV | |||
| ALL | LL | 50 ± 9 | 71(45.8) | 84(54.2) | 101(65.2) | 43(27.7) | 11(7.1) | 63 (40.6) | 92 (59.4) | 4(2.6) | 44 (28.4) | 85 (54.8) | 22 (14.2) |
| M | 46 ± 9 | 124(59.0) | 86(41.0) | 141(67.1) | 49(23.3) | 20(9.5) | 99 (47.1) | 111 (52.9) | 14(6.7) | 69 (32.9) | 93 (44.3) | 34 (16.2) | |
| P | 0.413 | 0.103 | 0.395 | 0.859 | 0.326 | ||||||||
| Premenopausal | LL | 42 ± 6 | 41(58.6) | 23(32.9) | 6(8.6) | 39 (55.7) | 31 (44.3) | 3(4.3) | 19 (27.1) | 36 (51.4) | 12 (17.1) | ||
| M | 40 ± 5 | 75(61.0) | 38(30.9) | 11(8.9) | 78 (63.4) | 45 (36.6) | 12(9.8) | 42 (34.1) | 48 (39.0) | 22 (17.9) | |||
| P | 0.137 | 0.642 | 0.182 | 0.116 | |||||||||
| Postmenopausal | LL | 57 ± 5 | 60(71.4) | 19(22.6) | 5(6.0) | 23 (27.4) | 61 (72.6) | 1(1.2) | 24 (28.6) | 49 (58.3) | 10 (11.9) | ||
| M | 56 ± 5 | 66(76.7) | 11(12.8) | 9(10.5) | 20 (23.3) | 66 (76.7) | 2(2.3) | 27 (31.4) | 45 (52.3) | 12 (14.0) | |||
| P | 0.527 | 0.369 | 0.212 | 0.792 | |||||||||
| First-degree family history of breast cancer | Ever been pregnant | Smoking status | Alcohol drinker | Case by stage | Estrogen Receptor(ER) status | Progesterone Receptor(PgR) status | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Yes | No | Yes | No | Yes | No | Yes | Local | Advanced | ER+ | ER- | PgR+ | PgR- | ||
| ALL | LL | 147(94.8) | 8(5.2) | 147 (94.8) | 8(5.2) | 146 (94.2) | 9 (5.8) | 142 (91.6) | 13 (8.4) | 56 (36.1) | 99(63.9) | 48(31.0) | 107 (69.0) | 56 (36.1) | 99(63.9) |
| M | 200(95.2) | 10(4.8) | 203 (96.7) | 7(3.3) | 191 (91.0) | 19 (9.0) | 191 (91.0) | 19 (9.0) | 77 (36.7) | 133(63.3) | 57(27.1) | 153 (72.9) | 62 (29.5) | 148(70.5) | |
| P | 0.828 | 0.297 | 0.664 | 0.296 | 0.421 | 0.882 | 0.364 | ||||||||
| Premenopausal | LL | 66(94.3) | 4(5.7) | 63 (90.0) | 7(10.0) | 62 (88.6) | 8 (11.4) | 59 (84.3) | 11 (15.7) | 39 (55.7) | 31(44.3) | 23(32.9) | 47 (67.1) | 30 (42.9) | 40(57.1) |
| M | 117(95.1) | 7(5.7) | 118 (95.9) | 6(4.9) | 106 (86.2) | 18 (14.6) | 108 (87.8) | 16 (13.0) | 64 (52.0) | 60(48.8) | 36(29.3) | 88 (71.5) | 39 (31.7) | 85(69.1) | |
| P | 0.464 | 0.154 | 0.668 | 0.187 | 0.763 | 0.989 | 0.220 | ||||||||
| Postmenopausal | LL | 80(95.2) | 4(4.8) | 83 (98.8) | 1(1.2) | 83 (98.8) | 1 (1.2) | 81 (96.4) | 3 (3.6) | 16 (19.0) | 68(81.0) | 24(28.6) | 60 (71.4) | 24 (28.6) | 60(71.4) |
| M | 83(96.5) | 3(3.5) | 85 (98.8) | 1(1.2) | 85 (98.8) | 1 (1.2) | 83 (96.5) | 3 (3.5) | 13 (15.1) | 73(84.9) | 21(24.4) | 65 (75.6) | 23 (26.7) | 63(73.3) | |
| P | 0.436 | 0.946 | 0.898 | 0.427 | 0.680 | 0.765 | 0.869 | ||||||||
BMI, body mass index; AJCC, American joint committee on cancer.